Purpose: Diffusion-weighted imaging (DWI) and 18 F-fluorodeoxyglucose-positron emission tomography ( 18 F-FDG-PET) independently correlate with malignancy in breast cancer, but the relationship between their structural and metabolic metrics is not completely understood. This study spatially correlates diffusion, perfusion, and glucose avidity in breast cancer with simultaneous PET/MR imaging and compares correlations with clinical prognostics. Methods: In this Health Insurance Portability and Accountability Act-compliant prospective study, with written informed consent and approval of the institutional review board and using simultaneously acquired FDG-PET and DWI, tissue diffusion (D t ), and perfusion fraction (f p ) from intravoxel incoherent motion (IVIM) analysis were registered to FDG-PET within 14 locally advanced breast cancers. Lesions were analyzed using 2D histograms and correlation coefficients between D t , f p , and standardized uptake value (SUV). Correlations were compared with prognostics from biopsy, metastatic burden from wholebody PET, and treatment history. Results: SUVjjD t correlation coefficient significantly distinguished treated (0.11 6 0.24) from nontreated (À0.33 6 0.26) patients (P ¼ 0.005). SUVjjf p correlations were on average negative for the whole cohort (À0.17 6 0.13).
INTRODUCTION
Breast cancer often is radiologically apparent by a decrease in apparent diffusion coefficient (ADC) compared to surrounding fibroglandular tissue on diffusion-weighted MRI (1) (2) (3) (4) . The addition of intravoxel incoherent motion (IVIM) analysis elaborates on the single component ADC model by adding another term to account for signal loss in a diffusionweighted sequence due to microvascular incoherent blood flow from tumor microvessels (5, 6) . The resulting IVIM biexponential model is expressed in three parameters: tissue diffusion (D t ), perfusion fraction (f p ), and pseudo diffusion (D p ). It has been shown that breast cancer is associated with reduced D t and higher f p compared with benign lesions (7) (8) (9) (10) (11) (12) (13) because this indicates increased cellularity and vascularity, respectively.
Positron emission tomography (PET) using the tracer 18 F-fluorodeoxyglucose (FDG) demarcates enhanced glucose uptake and subsequent phosphorylation, and is widely used clinically for the detection of nodal or distant metastases in breast cancer (14) . However, the sensitivity of FDG-PET to the physical tumor microenvironment and its relation to molecular prognostic factors (15, 16) are not completely understood. Correlative multicontrast studies are one route to shedding light on this issue.
T1-weighted MRI of the breast with a gadoliniumbased contrast agent offers volumetric millimeter-scale resolution and high signal-to-noise ratio, and is commonly used for breast cancer screening, staging, and assessment of the size of breast cancers (17, 18) . Moreover, its high resolution and contrast properties make this modality a clear choice for the delineation of lesion boundaries.
The structural and physiological environment of tumors is heterogeneous and different from the surrounding healthy tissue. These differences are a result of irregular angiogenic patterns, cellularity, enhanced metabolism, and proliferation of cancer. These heterogeneities in breast and other cancerous lesions can be quantified using FDG-PET (19) and MRI (20) (21) (22) (23) (24) (25) by texture analysis, segmentation, and 1D histogram analysis, from which metrics can be derived to serve as biomarkers for tumor type or efficacy of drug delivery and response to chemotherapy.
The respective microstructural and physiologic parameterization available from diffusion-weighted imaging (DWI) and FDG-PET can be facilitated by coregistering the image volumes from these modalities. Although these modalities can be independently applied and then registered, there is greater uncertainty that local blood flow and metabolism would be unaltered between scans. For instance, local hypoxia has been shown to change in a matter of minutes in preclinical imaging of a glioma line (26) . One may expect that flow and nutrient delivery may also see such dynamics. The recent clinical introduction of integrated PET/MR systems (27) enables acquisition of both modalities simultaneously in human subjects and generation of correlated description of a lesion on a voxelwise basis (28) .
Taken together, the aforementioned imaging modalities offer a means to delineate and describe metabolic and structural characteristics of breast cancer. Studies in breast and other cancers have suggested that there may be interrelationships at the group level between measures of diffusion and standard uptake value (SUV) (29-32), but they are moderate and variable, implying relationships beyond the canonical inverse correlation of ADC and SUV. By studying the complementary information offered by FDG-PET and DWI, there may prove to be analyses that differentiate lesions' diagnoses, prognoses, or responsiveness to treatment.
In this study, an integrated PET/MR system was used to assess the intermetric relationships and intralesional heterogeneity of coregistered IVIM and FDG metrics in breast cancer, with the goals of 1) categorizing the observed heterogeneity; and 2) comparing IVIM and SUV parametric information with established clinical prognostic factors, presence of metastases, and treatment history.
METHODS

Patient Population
In this institutional review board-approved and Health Insurance Portability and Accountability Act-compliant study with written informed consent, 21 women (age 25 to 79, average 49 6 14 years) with histopathologically confirmed breast cancer were imaged over a 1.5-year period (9/18/12-2/21/14) in a simultaneous PET/MR system (details in Image Acquisition) with residual FDG from immediately preceding clinical FDG PET/CT. The recruitment criteria for these patients included 1) whole-body PET/MR staging to explore an alternative to PET/CT, 2) clinical MRI of the local breast lesion either for presurgical or treatment planning or midtreatment follow-up, and/or 3) research and development of new diagnostic/prognostic tools from simultaneous PET/MR in the breast cancer population. Five scans showed insufficient fat suppression or other artifact on diffusionweighted imaging: one scan did not include axial postcontrast imaging and one scan featured a lesion with insufficient PET activity for registration. Eleven patients underwent a PET/MR for staging of disease. One patient underwent neoadjuvant chemotherapy. The PET/MR was performed to assess for response to treatment. This patient was scanned once before and once after chemotherapy (6-month interval between scans). In the included cohort (14 patients, 1 imaged twice; aged 25 to 66; average 46 6 12 years), one index lesion per patient was analyzed exclusively and consisted of 10 invasive ductal carcinomas (IDCs) (1 scanned twice), one IDC/ductal carcinoma in situ, and three invasive lobular carcinomas (1 pleomorphic). The patients had a mixture of disease progression, with three patients having no progression beyond the index lesion and 11 having nodal involvement or distant metastases at the time of exam. The following prognostic factors were available from standard workup of surgical or biopsy specimens: Her2/neu, estrogen receptor (ER), progesterone receptor (PR) level, and proliferation factor (Ki-67) expression. Seven patients received no chemotherapy, and eight received chemotherapy prior to imaging. Seven of the eight treated patients and five of the seven untreated patients were metastatic. Chemotherapy regimens varied accordingly with the heterogeneity in histology and prognostic factors of the tumor and included hormone therapy and cytotoxic treatment. Results from the whole body PET/ MR evaluation (33) or local DCE-MRI (34) of these patients have recently been reported, and in some cases they provided the metastatic burden assessment considered in the present study.
Image Acquisition
The subjects were imaged using an integrated 3T PET/ MR Biograph mMR (Siemens Healthcare, Erlangen, Germany) using a four-channel breast coil (35) (Noras, W€ urzburg, Germany) and residual FDG from immediately preceding clinical FDG PET/CT. The patients were in the prone position, and each patient was bilaterally imaged with a prototype twice-refocused spin echo echo-planar imaging axial DWI sequence (repetition time/echo time [TR/TE] ¼ 5,400/85 ms; matrix 192; 10 slices; bandwidth 1,736 Hz/px; 3 averages) with online eddy-current distortion correction provided by vendor software (36) and spectral attenuated inversion recovery in combination with a slice gradient reversal fat suppression technique at 10 b values (0, 30, 70, 100, 150, 200, 300, 400, 500, 800 s/mm 2 ) over the entire volume of the lesion. This was followed by injection of gadolinium contrast (Magnevist, Bayer HealthCare LLC, Whippany, NJ) and a subsequent axial T1-weighted volume interpolated breathhold examination sequence (T1Cþ). The T1Cþ sequence (TR/TE ¼ 4.7/1.6 ms, matrix 320, 95 slices) used either a standard Cartesian k-space sampling or a golden-angle radial sparse parallel MRI sequence, in either prototype or standardized form, with custom in-house reconstruction (37) . The DWI and T1Cþ images were initially reconstructed with voxel sizes of 1.8 Â 1.8 Â 4 mm and 1 Â 1 Â 1 mm to 2 mm, respectively.
The FDG-PET acquisition consisted of a single 15-min thorax position starting at the commencement of the local exam and overlapped with the DWI acquisition. The injected activities ranged from 478 to 561 MBq (average 533 MBq) and the start time of PET/MR imaging following injection ranged from approximately 2 to 4 hours (average 2 hours 55 min). Each image was corrected for attenuation using patient-specific and breast coil m-maps (35) . The PET images were reconstructed using 3D ordinary Poisson-ordered subsets estimation maximization (38) with a voxel size of 4.2 Â 4.2 Â 2 mm. Figure 1 illustrates the processing pipeline of this study following acquisition. The T1Cþ, DWI, and PET volumetric images were imported into FireVoxel (New York University [NYU], New York, NY). The entire lesion was segmented in FireVoxel (NYU) on the T1Cþ volume using the contrast enhancement to define the lesion boundaries by a single radiologist blinded to pathology (A.C.P.) for all lesions. A pixel mask was then generated in the same coordinate frame for later processing. Using FireVoxel (NYU), the PET and DWI were independently registered to the T1Cþ volume as follows: In both cases, the registration process used a mutual information criterion restricted to a 3D-dilated (radius 5 mm) lesion mask segmented on the T1Cþ. In some cases (1 for DWI; 2 for PET), the segmentation volume itself was used as registration target due to weak contrast in the DWI or PET images. For DWI, a 3D affine transformation with rigid body translation along three dimensions and, in order to mitigate image distortion, stretching along the anterior-posterior phase-encoding direction, was performed to align the lesion volume to T1Cþ. The highest b value image was used as the target volume, and all b value volumes used the same registration parameters. For PET, a rigid body 3D-registration was performed to align the lesion to the T1Cþ volume. Because the near-simultaneous acquisition should provide an inherent first-order alignment between the T1Cþ and PET/DWI, these registrations served to compensate for uncorrected DWI spatial distortion and any patient movement between the acquisitions of the T1Cþ and the other two modalities. The registered images were resampled and interpolated by FireVoxel (NYU) to match the coordinate frame and matrix dimensions of the T1Cþ such that the DWI and PET images were then coregistered with each other via the higher resolution T1-weighted postcontrast image. Finally, the segmented lesion volumes on DWI and PET were cropped and saved for further processing to conserve memory.
Image Analysis
The coregistered DWI, PET, and pixel mask volumes were imported into IGOR Pro (version 6.34; WaveMetrics, Lake Oswego, OR) and analyzed using in-house custom software. From the DWI, ADC maps were derived for each voxel with monoexponential analysis. Using a biexponential model and technique previously described (13), each DWI voxel was fitted across all b values to determine tissue diffusion (D t ), perfusion fraction (f p ), and pseudo diffusion (D p ) over the contoured lesion, as defined by the pixel mask:
The raw PET image values were converted to standardized uptake value (SUV) using total body mass, time from injection, and instrumental calibration factors. The correlating voxel SUVs were recorded from the PET data. All regions of the contoured lesion were included in the analysis unless they could not be fitted into one of the IVIM parameters. The total number of voxels in the segmented lesion was quantified as a measure of lesion size and computed using the T1Cþ voxel volume in cubic centimeters (cc).
For the registered data, 2D histograms were generated in IGOR Pro (WaveMetrics) for all lesion voxels with 0.01 < ADC, D t < 3 mm 2 /ms, 0 < f p < 0.75, and 0.01 < D p < 100 mm 2 /ms in each lesion by using 100 bins that were over a range of SUVs from zero to 10% larger than the SUV maximum, and 100 bins that were over the aforementioned ranges of ADC and IVIM parameters. One-dimensional histogram mean, maximum, minimum, standard deviation (SD), skewness, and kurtosis values were also determined for each metric, as previously described (13) .
The qualitative behavior of the 2D histograms of SUV versus D t and SUV versus f p were inspected. Secondly, the Pearson correlation coefficients (R) of cross-plots of the two metric pairs with each lesion voxel contributing one point were calculated. Lesions were plotted based on their R between SUV jj D t and between SUV jj f p .
Statistics
Pearson correlation coefficients were calculated between SUV and the diffusion metrics using IGOR Pro (WaveMetrics) for each lesion. For comparison of imaging metrics and prognostic factors (ER, PR, Her2/neu, and Ki-67), both group comparisons and correlations were performed. Pearson correlation coefficients between 1D histogram metrics or cross-correlation coefficients and prognostic factor values were determined. Student t tests were performed for each imaging metric between groups defined by binary classifications of each prognostic factor, metastatic status, and treatment status. For prognostic factors, positivity was defined as >10% ER, PR, or Ki-67 expression, and Her2/neu > þ1. Significance was considered P < 0.05 for this study. Statistical Package for the Social Sciences (SPSS) (version 20; SPSS, Chicago, IL) was used for statistical calculations, unless otherwise noted.
RESULTS
The image registration pipeline illustrated in Figure 1 was successful for 15 malignant lesions evaluated in this study (94% of those with complete artifact-free datasets). The segmented lesion volumes ranged from 1.2 to 34.9 cc, with a mean volume of 9.9 6 9.3 cc. Table 1 shows the 1D histogram metrics from ADC, IVIM, and SUV parameters across the whole lesion group. The prognostic factor groupings in this cohort, as defined in the statistics section, were: ER (12 of 15 positive), PR (7 of 15 positive), Her2/neu (6 of 15 positive), and Ki-67 (8 of 12 positive of patients with available data). Multiple feature prognostic distribution was as follows: for ERþ/PRþ/Her2þ, one treated /one untreated; for ERþ/PRþ/Her2À, three treated/two untreated; for ERÀ/PRÀ/Her2À, 0 treated, three untreated; for ERþ/PRÀ/Her2þ, four treated/0 untreated; and for ERþ/PRÀ/Her2À, one untreated.
The 2D histograms showed varying relationships with SUV against the IVIM parameters across the different lesions, six of which can be seen in Figures 1 and 2 , with correlation coefficients for all lesions summarized in Table 2 and illustrated in Figure 3 . The appearance of SUV against ADC and D t was in many cases a negative trend of varying strength. The Pearson R values reflect this with a mean value for all imaged lesions of À0.16 for SUVjjADC and À0.10 for SUVjjD t . The SUVjjf p correlations showed a negative trend, with a mean R of À0.17 for all lesions. SUVjjD p exhibited heterogeneous trends with lesions showing positive, negative, or no correlation with an overall correlation of À0.02. When stratified by treatment status, significant differences in SUVjjD t and SUVjjADC correlations were observed between treated and untreated lesions ( Table 2) (Fig. 3) , with untreated lesions displaying a more negative correlation.
The patient scanned both before and after treatment is also indicated in Figure 2 , showing a clear change in SUVjjD t correlation. Larger lesions tended to show SUVjjf p correlations closer to 0 than smaller masses, which displayed negative correlation coefficients. Table 3 shows results of group comparison and correlation analysis between imaging metrics and prognostic factors/clinical status. Apparent diffusion coefficient metrics showed significant correlation with Ki-67 expression, with average ADC negatively correlating and skewness/kurtosis positively correlating. Pseudodiffusion D p metrics showed opposite correlation trends with Ki-67 compared to ADC. Average, maximum, and SD of SUV correlated negatively with hormone (ER/PR) expression. Maximum f p and SUV kurtosis correlated positively with lesion size. Pseudo diffusion skewness and SD showed significant differences between patients with and without metastases. For 2D correlation metrics, SUVjjADC and SUVjjD t R values correlated positively with ER and Her2/neu expression levels. SUVjjf p R values correlated positively with lesion size. Finally, SUVjjADC and SUVjjD t R values showed significant differentiation of treated and nontreated patients. 
DISCUSSION
The 1D histogram parameters showed the expected reduction of tissue diffusion compared with ADC when the two-compartment model is incorporated. The relative SDs of D p (22%) and f p (30%) compared with D t (22%) for the malignant lesions are comparable or smaller than literature reports in larger cohorts (8, 10, 11, 13) . The correlations observed between prognostic factors and 1D IVIM or SUV histogram metrics aligned with findings in breast cancer patient groups (13, (39) (40) (41) . The negative correlation between ADC and proliferation index Ki-67 is consistent with the inverse relation of cell density and ADC. The negative correlation of SUV with hormonal receptor (ER/PR) expression also has been previously described (42) . By individual IVIM or SUV metrics, this group generally represents lesions of similar malignancy that are not significantly different from each other. As indicated in Table 3 , no single parameter from IVIM or PET significantly distinguished treated from nontreated lesions. The next-level analysis (2D correlations of IVIM and SUV) was performed to further characterize their individuality.
The 2D histogram analysis reveals relationships between SUV, diffusion, and perfusion fraction that are not revealed in analysis of means or other 1D histogram metrics. Regarding the SUVjjD t correlation, we observe that slightly over half of the lesions display the canonical negative intralesion correlation between SUV and D t , which often is observed at the group level (29) (30) (31) (32) . These lesions tended to be treatment-na€ ıve and thus displayed time points of an uninterrupted growth process in its early stages, retaining a strong link between cell density and glucose metabolism. The limiting asymptotic appearance of SUV against diffusion in many lesions suggests that some areas have reached a maximal cellular packing, as predicted in integrated logistic growth and diffusion models (43) . This also compares favorably with Byun et al. (30) , who demonstrated only a weak negative correlation (R > À0.3) between maximum SUV and mean or minimum ADC using sequential FDG-PET and DWI in women with IDC, although that study used a whole lesion analysis for maximum SUV and a single representative slice for ADC. In the treated lesions, all of which received some form of cytotoxic chemotherapy, the SUVjjD t correlations were near 0 or positive, arising either from a maximally packed cell density for all SUVs or a heterogeneous mixture of necrosis, apoptosis, or fibroglandular or adipose tissue. All of these scenarios reflect a departure from the early growth model in which cell density is proportional to glucose metabolism.
Regarding the SUVjjf p intralesional correlations, there again are some universalities and some group variabilities. Figure 3 illustrates that most lesions display a negative correlation. Examples in Figure 2 reveal different histogram patterns surrounding this negative trend, but most show higher SUVs occurring at smaller perfusion fraction (f p ) levels. Avril et al. (15) posited that beyond a certain cellularity, uptake of glucose in breast cancer no longer correlates with the numerical density of tumor cells but inversely correlates with microvascular density. Using this combined with saturated cellularity as an end point for terminal lesion growth, the diffusionperfusion-metabolic correlations suggest that lesions with stronger limiting diffusion value and greater negative correlation of SUV with f p are more advanced in their development. Conversely, another trend, which is illustrated in Figure 3 and reflected in the significant correlations shown in Table 3 , is that larger lesions tend to have weaker negative, or positive, SUVjjf p correlations compared with smaller lesions. As shown in the example in Figure 2b , this may reflect the likelihood that a larger heterogeneous lesion, from either prolonged growth or treatment effect, is more likely to include both The differences between the lesion correlation signatures may have therapeutic implications. The high rate of glycolysis in cancer is thought to confer robustness to harsh environments and resistance to therapy via hypoxia and acidosis (44) . The highest SUVs of many lesions in this study show the lowest perfusions in the lesion, suggesting that the regions with less vascular supply are those that are metabolically most active and most robust. In contrast, a few lesions show approximately equal or greater perfusion at their highest SUVs compared with their lowest, and thus may be less conditioned to hypoxic/acidic environments in their most glucose avid regions. The simultaneous PET/MR platform and analysis of intratumoral correlations may reveal signatures of tumor growth and viability patterns related to treatment efficacy that would escape a routine average metric quantification. The 2D space shown in Figure 3 defines a framework by which early and subtle effects of treatment can be monitored and perhaps inform management strategies. This approach may have further applications with other PET tracers such as 18 F-fluorothymidine, which probes cellular proliferation.
Several limitations exist in this pilot study, including possible error in coregistration, differences in pointspread function between imaging modalities, and the heterogeneity and limited size of the population. No multiple comparisons corrections were performed in the statistical analysis of this pilot cohort, and not all findings here would be robust to such a correction; therefore, the results herein are best seen as uncovering new metrics of cancer characterization and motivating future studies to more deeply investigate their diagnostic performance in comparison with known biomarkers (e.g., ADC, SUV). In the treated patients, we did not separately consider particular chemotherapy regimens or duration between treatment time and scan time in this study. The timing of the study was not controlled to monitor early response to therapy, which may have impacted the lack of treatment differentiation by conventional DWI and PET metrics. The evaluation of patients following their clinical PET/CT led to longer than standard uptake times, which may have influenced SUVs. The simultaneously acquired T1Cþ, DWI, and PET data should not require additional registration but for the uncorrected spatial distortions caused by the inhomogeneity in the static magnetic field and patient movement over the course of the scan (due to the T1Cþ being acquired after the DWI/PET). The reduced contrast and anatomical resolution of the PET and DWI, combined with the spatial nonlinearities of the latter, would preclude a high-quality registration between the two modalities themselves without field-map or reversed phaseencoding corrections not included in these acquisitions (45) . By introducing T1Cþ imaging, improved lesion visualization and PET/DWI registration were achieved at the expense of requiring a third contrast (enhancement).
The difference in point-spread functions and voxel sizes between the PET, DWI, and T1Cþ introduces uncertainty into the parametric maps and subsequent analyses. The partial volume effect on the SUV in PET relative to higher resolution modalities is well known (46) . This blurring will increase the uncertainty along the vertical axis of the 2D histograms, as well as reduce volume contributions of isolated groups that are comparable to or smaller than the size of the point-spread of the original PET. The matrix resampling of the DWI and PET to the finer dimensions of the T1Cþ gives an artificial increase in resolution that is isotropic to all voxels within a given lesion, and also smooths the raw images as part of the matrix resampling. This may introduce error in parameter fitting if the diffusion-weighted voxel intensities vary over short-length scales. In the present work, we have not investigated the effects of each of these registration/interpolation workflow steps on the output metrics in detail. Despite these uncertainties, however, the results indicate coherent regions of heterogeneous metrics within the lesions that would be otherwise unobservable using whole lesion averages.
CONCLUSION
This proof-of-concept study has yielded descriptions of correlations between SUV, D t , and f p in breast cancer using a straightforward method. Through coregistration of FDG-PET and DWI of images, as well as the resulting histogram/correlation analysis, new insights into the metabolically and structurally heterogeneous tumor environment were achieved. This simultaneously acquired parametric approach supports future studies with more controlled recruitment criteria and timing to assess lesion behavior between diffusion and PET metrics, and their relationship to established clinical biomarkers and treatment response.
